Theratechnologies Inc T.TH

RE:RE:RE:Soleus

[Lee430]

If there ever was a company that needed an activist investor it’s Thera, my felling is that our BOD is not adhering to their fiduciary responsibility and Thera needs a new captian before it runs aground.

Qwerty54321 wrote:

It seemed aggressive to me as well but how much of the statement is legally required?  If they are actively buying/selling stock do they need to be public on their attempt to put a board member in or their proactive attempts to engage with the business directly? Does sound like they've lost patience though.

On the selling of company assets, isn't this effectively what THTX have been trying to do with partnering activity with liver disease and cancer? It's hard to know what they think they can bring. 

SPCEO1 wrote: Here is the full thing from Soleus' 13D filing:

The Reporting Persons purchased the shares of Common Stock beneficially owned by the Reporting Persons (the “Shares”) for general investment purposes based on their belief that the Shares, when purchased, represented an attractive investment opportunity. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer.

 

The Reporting Persons have engaged, and intend to continue to engage, in communications with the Issuer’s Board of Directors (the “Board”) and management team regarding the Reporting Persons’ investment in the Issuer and opportunities to enhance stockholder value, including the potential appointment to the Board of a candidate designated by the Reporting Persons and the engagement of an investment bank to help the Issuer explore strategic transactions that may involve the sale by the Issuer of some or all of its assets and/or a change of control of the Issuer.

 

The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions or otherwise.

 

The Reporting Persons have no present plan or proposal that relates to or would result in any other action specified in clauses (a) through (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

scarlet1967 wrote:

BRIEF-Soleus Capital Master Fund, L.P.- Have Engaged, And Intend To Continue To Engage, In Communications With Theratechnologies Inc Board

11/28/23 - 05:57 PM ET - Reuters

Nov 28 (Reuters) - Theratechnologies Inc:

* SOLEUS CAPITAL MASTER FUND, L.P.- HAVE ENGAGED, AND INTEND TO CONTINUE TO ENGAGE, IN COMMUNICATIONS WITH THERATECHNOLOGIES INC BOARD

* SOLEUS CAPITAL MASTER FUND, L.P. REPORTS 10.5% STAKE IN THERATECHNOLOGIES INC AS OF NOV 27 , 2023 - SEC FILING

* SOLEUS CAPITAL- CONTINUE TO ENGAGE WITH THERATECHNOLOGIES’S BOARD REGARDING POTENTIAL APPOINTMENT TO BOARD, A CANDIDATE DESIGNATED BY SOLEUS CAPITAL

* SOLEUS CAPITAL-MAY ENGAGE INVESTMENT BANK TO HELP THERATECHNOLOGIES EXPLORE STRATEGIC DEAL LIKE SALE OF SOME/ALL ASSETS AND/OR CHANGE OF CONTROL Source text for Eikon: Further company coverage:

The Reporting Persons purchased the shares of Common Stock beneficially owned by the Reporting Persons (the “Shares”) for general investment purposes based on their belief that the Shares, when purchased, represented an attractive investment opportunity. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer.

 

The Reporting Persons have engaged, and intend to continue to engage, in communications with the Issuer’s Board of Directors (the “Board”) and management team regarding the Reporting Persons’ investment in the Issuer and opportunities to enhance stockholder value, including the potential appointment to the Board of a candidate designated by the Reporting Persons and the engagement of an investment bank to help the Issuer explore strategic transactions that may involve the sale by the Issuer of some or all of its assets and/or a change of control of the Issuer.

 

The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions or otherwise.

 

The Reporting Persons have no present plan or proposal that relates to or would result in any other action specified in clauses (a) through (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.